Last week, the U.S. Food and Drug Administration approved the use of lumacaftor/ivacafter (Orkambi) for children with cystic fibrosis ages 6 to 11, who have two copies of the most common CF gene mutation, F508del. The decision means that about 2,400 additional children in the U.S. are eligible to receive the drug, bringing the total number of those eligible for the treatment in the U.S. to nearly 11,000. Go to cff to read the rest of the article on the CFF website.

Share this:

Leave a Reply